Depodur: profile and news
Evaluation of a Single-Dose, Extended-Release Epidural Morphine ... Feb 22, 2006
Background: DepoDur is a single-dose, extended-release epidural morphine formulation designed to provide forty-eight hours of pain relief. ... - Journal of Bone and Joint Surgery
Endo Pharmaceuticals Reports Fourth Quarter and Full-Year 2005 ... Feb 15, 2006
DepoDur(R). Net sales of DepoDur(R) were $0.9 million for the three months ended December 31, 2005 and $3.9 million for the twelve months ended December 31 ... - MSN Money
Endo Pharmaceuticals Reports Fourth Quarter and Full-Year 2005 ... Feb 15, 2006
DepoDur®. Net sales ... 31, 2005. The company began promoting DepoDur® in early 2005 with its 70-representative hospital sales force. ... - Yahoo! News (press release)
Business Digest Feb 25, 2006
A “warts and all� assessment of the firm’s portfolio is also likely to reveal a delay in the commercialisation of DepoDur, a morphine-based painkiller. ... - The Sunday Times,
SkyePharma Issues EGM Notice and Recommends Shareholders to Vote ... Feb 17, 2006
The injectables business, primarily located in San Diego, consists of two marketed products, DepoCyt(R) for a complication of cancer and Depodur(R) for the ... - PR Newswire (press release),
SkyePharma sinks as board defies rebels Feb 2, 2006
...strategic review, the company said it is instead opting to sell its injectable drugs division, which comprises cancer drug DepoCyt and Depodur for treating ... - Times Online,
SkyePharma defies rebels by appointing Karabelas to chair Feb 2, 2006
The division, which makes DepoCyt to treat a complication of cancer and Depodur for post-surgery pain, has attracted interest from several bidders and is worth ... - Independent,
SkyePharma Announces Appointment of New Chairman and Outcome of ... Feb 2, 2006
The injectables business, primarily located in San Diego, consists of two marketed products, DepoCyt® for a complication of cancer and Depodur® for the ... - Yahoo! News (press release)
SkyePharma sinks as board defies rebels Feb 2, 2006
...strategic review, the company said it is instead opting to sell its injectable drugs division, which comprises cancer drug DepoCyt and Depodur for treating ... - Times Online,
SkyePharma defies rebels by appointing Karabelas to chair Feb 2, 2006
The division, which makes DepoCyt to treat a complication of cancer and Depodur for post-surgery pain, has attracted interest from several bidders and is worth ... - Independent,
SkyePharma Announces Appointment of New Chairman and Outcome of ... Feb 2, 2006
The injectables business, primarily located in San Diego, consists of two marketed products, DepoCyt(R) for a complication of cancer and Depodur(R) for the ... - PR Newswire (press release),
Endo leases marketing rights for new drug Jan 10, 2006
The drug will be promoted through Endo’s existing 70-person hospital sales force, which currently promotes DepoDur, Lankau said. ... - Chester Daily Local Online,
Endo Announces License Agreement With ZARS for Synera(TM), an FDA ... Jan 9, 2006
...setting." He noted that Endo will promote Synera(TM) through its existing 70-person hospital sales force, which currently promotes DepoDur® (morphine sulfate ... - Yahoo! News (press release)
SkyePharma PLC (LSE: SKP; Nasdaq: SKYE) Announces Interim ... Sep 28, 2005
...launch of Triglide(TM) (fenofibrate) - New agreement with GlaxoSmithKline on Paxil CR(TM) - Paxil CR(TM) returned to US market 27 June - DepoDur(TM) granted ... - PR Newswire (press release),
New Drug Makes Recovery Time Faster Following Surgery Oct 3, 2005
...hours. The drug, six years in the making, is called DepoDur, and it's designed for extended pain treatment for up to 48 hours. “I ... - KAIT,
Biotech industry seeks cure for insider dealing threat Aug 20, 2005
The new product, called DepoDur, passed its clinical safety tests and was cleared by regulators; hedge funds that had tried to exploit SkyePharma's predicted ... - The Observer,
